Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Cephalon history
Cephalon company history timeline
In March 1991 the staff had grown to 49 employees, who worked in an enlarged 31,000-square-foot lab.
In late 1991 Cephalon received orphan drug approval for its product Myotrophin.
1991: Cephalon goes public with a $59.4 million IPO.
In addition, the first step toward the development of the narcolepsy treatment Provigil was taken in February 1993, when Cephalon bought from the French company Laboratoire L. Lafon all rights to develop, market, and sell Provigil's main ingredient, modafinil.
Meanwhile, a successful $23 million equity offering in April 1993 showed that investors retained confidence in Cephalon.
Shaw, Donna, “Pennsylvania Biotech Company Cephalon’s Research Continues to Boost Revenues,” Knight-Ridder/Tribune Business News, May 17, 1994.
1995: Cephalon establishes a sales force.
The first major stumbling block for Myotrophin came at the beginning of 1996, when the FDA refused to allow Cephalon to expand tests of the drug.
In 1996 Cephalon sold the plant that it had been using to manufacture Myotrophin.
The company finally gave up on the drug in 1999, disappointing both the National ALS Association, which had hoped the drug could become an effective treatment, and ALS patients who had been given special access to Myotrophin.
In January 2000 test results were announced showing that the drug was effective in warding off fatigue in multiple sclerosis patients and shift workers.
Cephalon acquired worldwide product rights to the drug in October 2000 through its merger with Anesta Corporation of Salt Lake City.
In collaborations with such international partners as TAP Holdings, Kyowa Hakko Kogyo, H Lundbeck, and, as of December 2000, the R.W. Johnson Pharmaceutical Research Institute, the company was researching kinase inhibitors, compounds that either enhance cell survival or cause cell death.
2001: Rights to Gabitril are acquired.
"Cephalon, Inc. ." International Directory of Company Histories. . Retrieved June 22, 2022 from Encyclopedia.com: https://www.encyclopedia.com/books/politics-and-business-magazines/cephalon-inc
Rate Cephalon's efforts to communicate its history to employees.
Cephalon jobs
Do you work at Cephalon?
Does Cephalon communicate its history to new hires?
Cephalon competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gilead Sciences | 1987 | $28.8B | 11,800 | 635 |
| Merck | 1891 | $64.2B | 74,000 | 2,154 |
| Regeneron | 1988 | $14.2B | 9,123 | 421 |
| Zoetis | 1952 | $9.3B | 11,300 | 272 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 254 |
| Seagen | 1997 | $2.0B | 900 | - |
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| SIGA Technologies | 1995 | $115.5M | 43 | - |
| Pfizer | 1849 | $63.6B | 78,500 | 602 |
| Zeneca, Inc. | 1970 | $22.1B | 76,100 | - |
Cephalon history FAQs
Zippia gives an in-depth look into the details of Cephalon, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Cephalon. The employee data is based on information from people who have self-reported their past or current employments at Cephalon. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Cephalon. The data presented on this page does not represent the view of Cephalon and its employees or that of Zippia.
Cephalon may also be known as or be related to Cephalon, Cephalon Inc, Cephalon Inc. and Cephalon, Inc.